Beverly L. Davidson is a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania. She serves as Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics and Chief Scientific Strategy Officer at the Children's Hospital of Philadelphia Research Institute. Her work bridges molecular neuroscience, genetic disease research, and gene therapy innovation. Research Focus : Davidson's lab investigates neurodegenerative diseases and genetic disorders affecting the brain , with emphasis on RNA biology, gene therapy, and animal models of disease. The team develops novel adeno-associated virus (AAV) vectors for tissue-specific therapeutic delivery, focusing on diseases like ALS, Huntington’s, and Alzheimer’s. Scientific Leadership : Transformative Research Award (Hereditary Disease Foundation) George Stamatoyannopoulos Memorial Lecture (ASGCT) Publications : Her recent work highlights advances in AAV engineering, CRISPR applications, and molecular mechanisms of neurodegeneration, with a focus on clinical translation of gene therapies for brain disorders. Training & Mentorship : As a Penn faculty member, she mentors graduate students, including Bryan Simpson, who recently defended his thesis in her lab.
Angela Gritti is an Associate Professor of Human Histology at Vita-Salute San Raffaele University and a Group Leader at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET) since 2006. Her work focuses on genetic neurodegenerative diseases , particularly Leukodystrophies and GM2 gangliosidosis , using neural stem cells and gene therapy approaches. PhD in Basic Sciences and Veterinary Biotechnology (University of Turin, 2006) Specialty in Toxicology (University of Milan, 1996) Degree in Biological Sciences (University of Milan, 1990) Her research explores regenerative medicine and gene therapy through neural stem cell biology , focusing on: Pathogenesis of lysosomal storage disorders iPSC modeling of human CNS diseases AAV/lentiviral vector safety Epigenetic modulation of oligodendrocytes Preclinical development for metabolic CNS diseases The articles section reveals her contributions to gene therapy safety , iPSC neural modeling , and combined cell/gene strategies for leukodystrophies. Despite extensive grant reviewer roles (ERC, AFM Telethon, EJPRD) and international collaborations with institutions in France, Norway, and the USA, no formal scientific awards are listed in the current text. She has supervised 12 PhD students and 22 master's students while leading funded projects with institutions like the Bespoke Gene Therapy Consortium (NIH), European Leukodystrophy Association , and Italian Telethon Foundation . Her lab also contributes to patient advocacy through educational outreach and clinical translation frameworks.
Prof. Dr. Stylianos Michalakis is a faculty member at Ludwig Maximilian University of Munich (LMU Munich), specializing in Epigenetics and Bioinformatics . His research focuses on retinal gene therapy , mechanisms of retinal degeneration , and the therapeutic potential of adeno-associated virus (AAV) vectors . He leads investigations into inherited retinal diseases like Achromatopsia and Retinitis Pigmentosa , aiming to develop pharmacological and genetic neuroprotection strategies. Current research targets the role of cGMP and its downstream pathways in photoreceptor degeneration. Develops AAV-based vaccines and advanced vector engineering techniques for retinal delivery. Investigates CRISPR/dCas9-VPR systems for gene activation in inherited retinal dystrophies. His recent publications highlight innovations in AAV vector design, long-term therapeutic efficacy in animal models, and molecular diagnostics for retinal disorders. Key subfields include Retinitis Pigmentosa , Stargardt Disease , photoreceptor survival , and neuroinflammatory modulation . Collaborations span preclinical testing, clinical trials, and translational research in ophthalmology and molecular biology.
Dr. Jayandharan Giridhara Rao is a Professor in the Department of Biological Sciences & Bioengineering at the Indian Institute of Technology Kanpur (IIT Kanpur). He has been with IIT Kanpur since 2014, initially serving as an Associate Professor until December 2019, when he was promoted to Professor. Dr. Rao earned his PhD in Biomedical Sciences/Molecular Biology from Christian Medical College, Vellore in 2008. He completed his postdoctoral training at the Powell Gene Therapy Center, University of Florida, Gainesville, USA from 2007-2009. Dr. Rao's research program focuses on developing molecular medicine platforms to address unmet clinical needs for monogenic human diseases and cancers. His work interfaces at the basic biology of adeno-associated virus (AAV) and its translational science. He utilizes a variety of molecular, cellular, and preclinical models to advance gene therapy approaches. His expertise lies in viral vector engineering, particularly with AAV vectors, for therapeutic applications in hemophilia, retinal degeneration, and various cancers. Analysis of Dr. Rao's recent publications reveals a strong focus on engineering AAV vectors for improved therapeutic efficacy. His work spans multiple applications including hemophilia treatment, retinal degeneration therapy, and cancer treatment. He has made significant contributions to understanding post-translational modifications in viral capsids and their impact on gene delivery efficiency. Dr. Rao has received numerous prestigious awards and recognitions for his research: Senior Fellowship, Wellcome Trust DBT India Alliance (2017-22) B.M. Birla Science Prize in Biology (2015) Young scientist award, YIM-MIT Boston, USA (2014) Senior Innovative Young Biotechnologist award, Department of Biotechnology, Government of India (2014-17) Swarnajayanti Fellowship, Department of Science and Technology, Government of India (2012-17) Bayer Hemophilia Early Career Investigator Award, Bayer Inc, USA (2010-12) While specific details about his advising and grant history are not provided in the available information, Dr. Rao's extensive publication record and prestigious fellowships suggest a robust research program with significant funding support. His work appears to bridge basic virology with translational medicine, positioning him as a key contributor to the field of gene therapy in India. Dr. Rao's laboratory likely focuses on viral vector engineering and preclinical testing of gene therapy approaches, though specific details about his lab structure and team composition are not provided in the available information.
Hannah Hoeun Lee, MD, PhD, is an Assistant Professor of Orthopaedic Surgery at the Perelman School of Medicine, University of Pennsylvania , affiliated with the Orthopaedic Surgery Department at Pennsylvania Hospital. Her research spans orthopaedics, hand surgery, and bioengineering. Education : BS in Chemical and Biomolecular Engineering (Cornell, 2006), PhD in Bioengineering (Pitt, 2014), MD (Pitt, 2014) Recent work focuses on osteoarthritis progression , nerve injury treatments , and socioeconomic disparities in hand surgery care . She explores gene therapy for cartilage repair and opioid-free pain management strategies. Publications highlight collaborations on surgical outcomes, imaging techniques, and tissue engineering. Her clinical interests include hand surgery , cartilage pathology , and musculoskeletal rehabilitation . No awards or part-time status are mentioned.
Paris Margaritis, DPhil, is an Investigator at the CHOP Research Institute within the Department of Pediatrics and Division of Hematology . He leads the Margaritis Laboratory , focusing on coagulation disorders, particularly hemophilia, using biochemical, molecular, and in vivo methodologies to study pro- and anti-coagulant reactions. Email : margaritis@chop.edu The Margaritis Lab developed a groundbreaking model involving enhanced FVIIa expression via gene transfer, achieving phenotypic correction in hemophilia models. They also engineered species-specific reagents for monitoring hemostatic effects and investigate molecular interactions between FVIIa and its binding partners, with implications for FVIIa-based therapeutics. Scientific Awards : Bayer Award (2017) for advancing hemophilia research His work spans gene therapy, protein engineering, and translational strategies for coagulation defects, leveraging in vitro and in vivo techniques to visualize real-time FVIIa reactions. The lab’s research includes viral transduction, hemostatic endpoints, and therapeutic design for hemophilia treatments.
David Paul Corey serves as the Bertarelli Professor of Translational Medical Science at Harvard Medical School's Department of Neurobiology. His research focuses on mechanotransduction in vertebrate hair cells, particularly the structural and functional analysis of tip-link proteins (CDH23, PCDH15) and transduction channels (TMC1/2). The Corey Laboratory develops gene therapies for Usher syndrome and hereditary deafness using advanced techniques including X-ray crystallography Single-molecule force spectroscopy Adeno-associated viral vectors Cryo-electron microscopy Current translational work targets Usher syndrome type 1F through dual-AAV delivery systems and base editing approaches. The lab employs multidisciplinary methods combining biophysics , molecular genetics , and nanomechanical modeling to understand and treat sensory deficits. Recent publications highlight breakthroughs in Mini-PCDH15 protein design Primate gene therapy safety Transduction channel pore characterization Therapeutic force spectroscopy with ongoing clinical translation efforts. Scientific distinctions include: Bertarelli Foundation Professorship NIH grant collaborations Leadership in mechanotransduction
Professor Robyn Jamieson serves as Professor of Genomic Medicine and Head of the Specialty of Genomic Medicine at The University of Sydney's Children's Hospital at Westmead Clinical School. She is a member of The University of Sydney Nano Institute and maintains strong affiliations with the Save Sight Institute and Children's Medical Research Institute. Her clinical specialty is Genetic Medicine with a focus on pediatric ophthalmology and inherited eye disorders. Professor Jamieson's research program centers on genomic and functional studies aimed at understanding disease causation in genetic eye diseases, particularly those affecting the retina. Her work has resulted in several novel disease gene and variant identifications, new insights into disease mechanisms, and translation to diagnostic genomic testing for genetic eye diseases. She actively pursues applications in genome engineering and new vector technologies for developing therapies for blinding eye conditions. Her research spans themes of Reproductive, Maternal and Child Health; Neurosciences and Mental Health; and Healthy Ageing, employing approaches in Cellular/Molecular biology, Genetics, and Translational Research. Analysis of Professor Jamieson's recent publications reveals a strong focus on inherited retinal diseases, with significant work on gene identification (GUCY2D, PROM1, KCNV2, WNT7B), natural history studies, biomarker development, and therapeutic approaches. Her research increasingly incorporates advanced technologies including AAV capsid bioengineering, retinal organoids, and genome sequencing for improved diagnosis and treatment pathways. The work spans basic science through to clinical implementation and health economics. Professor Jamieson actively supervises research students including Nadya ANDHIKA (exploring genetic therapy approaches in inherited retinal dystrophy) and William YATES (working on inherited retinal disease natural history and gene therapies). She has secured substantial grant funding from NHMRC, Department of Health, and other sources for projects including 'Resolving genetic variant uncertainty in syndromic and non-syndromic retinitis pigmentosa,' 'DEVELOPMENT OF PHOTORECEPTOR CELL THERAPY TO TREAT BLINDNESS,' and 'ALPK1 dysfunction: revealing a novel pathogenic pathway in retinal diseases.'
Dr. Jacquelyn Bower is an Assistant Professor in the Department of Ophthalmology at the University of North Carolina at Chapel Hill's School of Medicine. She is a member of the UNC Lineberger Comprehensive Cancer Center with research focused on developing therapeutic strategies for uveal melanoma and DNA damage-related pathogenesis. Her lab investigates mutations in GNAQ/GNA11 proteins that drive tumor proliferation and metastasis, currently advancing preclinical studies for targeted therapies. Education: • PhD in Basic Pharmaceutical Sciences from West Virginia University (CDC/NIOSH) • Postdoctoral Fellowship at University of North Carolina at Chapel Hill Research Focus: Dr. Bower's work centers on ocular oncology and gene therapy, particularly exploiting molecular defects in uveal melanoma for therapeutic intervention. She develops AAV-based vectors for ocular diseases, including immunomodulatory approaches for autoimmune uveitis and corneal transplantation. Her secondary focus involves breast cancer mechanisms through Lineberger Cancer Center collaborations. Publication Trends: Recent articles (2021-2025) demonstrate concentrated work on AAV vector optimization for ocular applications, including toxicity reduction, biodistribution studies, and mutation-specific targeting of uveal melanoma. Over 80% of publications involve preclinical gene therapy models for anterior/posterior eye diseases. Awards and Honors: Career Development Award – American Society for Cell and Gene Therapy (2022) IBM Junior Faculty Development Award (2021) NIH Clinical Research Loan Repayment (2014-2016) Postdoctoral Research Excellence Award – UNC (2010) Sigma Xi Research Competition Winner (2005) Lab and Collaborations: Dr. Bower leads the Bower Lab at the Carolina Eye Research Institute, focusing on translational ocular oncology. She collaborates with UNC's Hematology/Oncology and Epidemiology departments on breast cancer recurrence mechanisms and maintains active NIH/NCI grant support.
Anna Dimberg is Professor at Uppsala University's Department of Immunology, Genetics and Pathology, where she leads the Vascular Biology research program. Her laboratory investigates tumor vascular abnormalities in cancers, with particular emphasis on glioblastoma. The research examines how altered vessel phenotypes influence tumor microenvironments and therapy responses, focusing on endothelial cell biology and vascular-immune interactions. Her research integrates multiple approaches: Molecular characterization of tumor endothelial cells using single-cell RNA sequencing Development of vascular normalization strategies to improve immunotherapy Investigation of endothelial-immune cell crosstalk in tumor progression AAV-based gene therapies to remodel tumor vasculature Patient-derived iPSC models of vascular disorders Publication analysis reveals consistent focus on vascular biology mechanisms in cancer contexts. Recent work emphasizes: vascular checkpoint targets (CD93, ELTD1), immunotherapy combination strategies, endothelial barrier regulation, and single-cell characterization of tumor vasculature. The research has progressively incorporated spatial transcriptomics and advanced immune profiling techniques since 2020. The laboratory maintains active collaborations as evidenced by multi-institutional publications and investigates both fundamental vascular biology mechanisms and translational applications for cancer therapy.
Merja Voutilainen is an Adjunct Professor at the University of Helsinki's Faculty of Pharmacy, Division of Pharmacology and Pharmacotherapy. Her work spans pharmacology, neuroscience, and regenerative medicine, focusing on neurodegenerative diseases like Parkinson's and ALS. She supervises doctoral programs in Brain & Mind and Drug Research. Education: PhD in Pharmacology, University of Helsinki (2004-2010) Research Interests: Merja’s research centers on neuroprotection, remyelination, CDNF-based therapies, and gene transfer applications for dopamine neuron preservation. She also investigates biofouling prevention in neural implants and ER stress regulation in neurodegenerative models. Scientific Awards: Adjunct Professor (Docent) of Pharmacology and Drug Development (2016) Innoopeli Prize 2022 Grants & Collaborations: She has secured grants from the European Commission (ERC-POC), Sigrid Juséliuksen Säätiö, Jane and Aatos Erkko Foundation, and others. Collaborations include institutions in Finland and international partners.
Dr. Hande Ozdinler is an Associate Professor in the Ken & Ruth Davee Department of Neurology at Northwestern University's Feinberg School of Medicine, where she directs the Ozdinler Lab focused on upper motor neuron biology and pathology. Her research is supported by multiple institutional affiliations including the Chemistry of Life Processes Institute, Les Turner ALS Center, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, and the Northwestern University Institute of Neuroscience. Dr. Ozdinler earned her PhD from Louisiana State University Health Sciences Center in 2002. Her research career has been dedicated to understanding selective neuronal vulnerability, particularly in corticospinal motor neurons affected in diseases like ALS, primary lateral sclerosis, and hereditary spastic paraplegia. Her laboratory investigates multiple aspects of upper motor neuron health and disease, with major research thrusts in biomarker discovery, drug development (particularly the compound NU-9), high-throughput drug screening platforms, electrophysiological characterization of diseased neurons, and gene therapy approaches. Her work has revealed that NU-9 improves neuronal health by addressing protein aggregation, mitochondrial instability, and endoplasmic reticulum integrity issues across multiple neurodegenerative conditions. Analysis of Dr. Ozdinler's recent publications shows a strong focus on protein interactome analyses (particularly TDP-43 and spastin), mitochondrial dysfunction in ALS, high-resolution neuronal network analysis using microelectrode arrays, and the development of targeted therapeutic approaches for upper motor neuron diseases. Her research increasingly integrates multi-omics approaches to identify biomarkers and therapeutic targets. CLP Cornew Innovation Award, CLP at Northwestern (2022) INVO N.XT Award for Drug Discovery, Northwestern University (2017) One of 10 Most Innovative Research of 2015, International Innovation (2016) Top 30 Most Influential Turkish American Women in USA, Turk of America (2016) Dr. Ozdinler has mentored numerous students and postdoctoral fellows who have gone on to successful careers in academia, industry, and medicine. Her laboratory has received significant grant support, including a $3.1 million grant from the National Institute on Aging for ALS drug discovery research. She serves on editorial boards for Somatosensory and Motor Research and Clinical and Translational Neuroscience, and chairs AKAVA Therapeutics' scientific advisory board. The Ozdinler Lab maintains active collaborations with multiple research centers and has developed innovative approaches to studying upper motor neuron diseases, including high-density microelectrode array systems and novel gene delivery methods.
Juan Antonio Hernández Bort serves as a Senior Research Fellow at the Department of Analytical Chemistry within the Faculty of Chemistry at the University of Vienna, where he contributes to the Biochemical Network Analysis Team's research in molecular and cellular systems. His primary research focuses on: Gene Therapy: Development of viral vector-based delivery systems for therapeutic applications Adeno-Associated Virus: Engineering and optimization of AAV vectors for gene delivery Cell Biology: Investigation of fundamental cellular mechanisms and processes Molecular Biology: Analysis of molecular interactions and genetic regulation pathways Mammalian Cells: Utilization of mammalian cell models for experimental research Within the Biochemical Network Analysis Team, Dr. Hernández Bort collaborates with researchers including Jürgen Zanghellini and Elena Afanaseva on biochemical network modeling. His senior research position indicates active leadership in ongoing projects, though specific details about academic advising and grant funding are not disclosed in available materials.
Cristina Fornaguera Puigvert is a full professor at the IQS School of Engineering, University of Ramon Llull, specializing in the Department of Bioengineering. Her research focuses on nanotechnology applications for drug delivery, including nanoparticle-based strategies for neurodegenerative diseases, cancer therapy, and localized antitumor treatments. She leads multiple projects on biocompatible microcapsules and RNA-based vaccine characterization. Current Projects : Capsaromes: Microencapsulation of aromas for food industry TECARN: mRNA analysis for vaccination OCEANIC: Microplastic-free cosmetic microcapsules Research Trends : Recent work emphasizes therapeutic nanoparticles (gold, iron oxide), immunomodulation via viral vector engineering, and siRNA delivery systems for cancer treatment. Keywords include nanomedicine, drug delivery, and bioengineering. Scientific Awards ICREA Academy 2024 Collaborations : Active collaborations with researchers in Italy, Catalonia, and international institutions on nanoparticle functionalization and disease therapy.
Dibakar Bhattacharyya—known globally as "DB"—is the University Alumni Professor in the Department of Chemical Engineering and Director of the Center of Membrane Sciences at the University of Kentucky’s Stanley and Karen Pigman College of Engineering. Celebrating 50 years of service in 2017, he remains an internationally recognized leader in membrane science and water technologies. Education: Ph.D. Environmental Engineering, Illinois Institute of Technology, USA, 1966 M.S. Chemical Engineering, Northwestern University, USA, 1963 B.S. Chemical Engineering, Jadavpur University, India, 1962 Research Focus: DB’s group pioneers tunable membranes and biocatalytic systems for next-generation water treatment. Major thrusts include high-performance graphene-oxide and amine-functionalized membranes for PFAS detoxification, selective capture of noble metals from electronic-waste streams, and advanced micro/ultrafiltration platforms that clarify viral vectors for gene-therapy applications. Integration of catalytic layers with membrane pores enables simultaneous separation and reaction, pushing the boundary of reactive membrane filtration . His recent works (2022-25) exhibit a clear trend: multifunctional membranes engineered at the nanoscale to solve emerging environmental and biomedical challenges. PFAS remediation, viral-vector purification, and dual-use air/water cleaning filters dominate the portfolio, often coupled with techno-economic or CFD analyses to speed deployment. Current & Recent Support: Investigations are backed by NSF EPSCoR, NIEHS, NSF EAGER, Australian Research Council, Southern Co. and Chevron, among others, reflecting strong federal & industry confidence. Campus Leadership: DB co-chaired the 2018 North American Membrane Society Annual Meeting, bringing 400+ global experts to Kentucky, and continues to direct the interdisciplinary Center of Membrane Sciences.
